6533b82bfe1ef96bd128e0e5
RESEARCH PRODUCT
Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma.
Kyogo ItohChristoph RohdeÖZlem TüreciUgur SahinRin YamaguchiSvetlana Mukhinasubject
Cancer Researchmedicine.medical_specialtymedicine.medical_treatmentPopulationprevalenceAdenocarcinomaGastroenterologyAsian PeopleStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansRadiology Nuclear Medicine and imagingeducationLymph nodeIMAB362Chemotherapyeducation.field_of_studybiologybusiness.industrygastric cancerCancerAntibodies MonoclonalbiomarkersGeneral Medicinemedicine.diseaseImmunohistochemistryClaudinGene Expression Regulation Neoplasticmedicine.anatomical_structureOncologyLymphatic MetastasisClaudinsbiology.proteinImmunohistochemistryBiomarker (medicine)Original ArticleAntibodybusinessdescription
CLDN18.2 expression is highly prevalent in Japanese patients with gastric cancer, making it a targetable alteration, and supporting development of zolbetuximab as a therapeutic agent for this patient population.
year | journal | country | edition | language |
---|---|---|---|---|
2019-05-14 | Japanese journal of clinical oncology |